During the past decade, Palo Alto Medical Foundation-Gynecologic Oncology conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 62 clinical trials were completed, i.e. on average, 112.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 42 clinical trials were completed. i.e. 525% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Palo Alto Medical Foundation-Gynecologic Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 58 trials, followed by "SWOG Cancer Research Network" with 25 trials sponsored, "Gynecologic Oncology Group" with 11 trials sponsored, "Alliance for Clinical Trials in Oncology" with 9 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 9 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Palo Alto Medical Foundation-Gynecologic Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 60 trials as a collaborator, "NRG Oncology" with 24 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Agenus Inc." with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Palo Alto Medical Foundation-Gynecologic Oncology" are "Recurrent Ovarian Carcinoma" (11 trials), "Ovarian Seromucinous Carcinoma" (10 trials), "Recurrent Fallopian Tube Carcinoma" (9 trials), "Recurrent Primary Peritoneal Carcinoma" (9 trials) and "Recurrent Squamous Cell Lung Carcinoma" (9 trials). Many other conditions were trialed in "Palo Alto Medical Foundation-Gynecologic Oncology" in a lesser frequency.

Most popular intervention types in "Palo Alto Medical Foundation-Gynecologic Oncology" are "Drug" (95 trials), "Other" (84 trials), "Biological" (51 trials), "Procedure" (32 trials) and "Radiation" (11 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (51 trials), "Quality-of-Life Assessment" (34 trials), "Paclitaxel" (27 trials), "Carboplatin" (22 trials) and "Computed Tomography" (17 trials). Other intervention names were less common.

The vast majority of trials in "Palo Alto Medical Foundation-Gynecologic Oncology" are 71 trials for "All" genders, 45 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Palo Alto Medical Foundation-Gynecologic Oncology". undefined are not yet recruiting, 18 are recruiting, 63 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Palo Alto Medical Foundation-Gynecologic Oncology, 2 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Palo Alto Medical Foundation-Gynecologic Oncology, 2 "Phase 1" clinical trials were conducted, 63 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".